Show simple item record

dc.contributor.authorMoorman, Anthony V
dc.contributor.authorRichards, Susan M
dc.contributor.authorRobinson, Hazel M
dc.contributor.authorStrefford, Jon C
dc.contributor.authorGibson, Brenda E
dc.contributor.authorKinsey, Sally E
dc.contributor.authorEden, Tim O B
dc.contributor.authorVora, Ajay J
dc.contributor.authorMitchell, Christopher D
dc.contributor.authorHarrison, Christine J
dc.date.accessioned2009-06-30T11:54:28Z
dc.date.available2009-06-30T11:54:28Z
dc.date.issued2007-03-15
dc.identifier.citationPrognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). 2007, 109 (6):2327-30 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid17095619
dc.identifier.doi10.1182/blood-2006-08-040436
dc.identifier.urihttp://hdl.handle.net/10541/71935
dc.description.abstractPatients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.
dc.language.isoenen
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshChromosomes, Human, Pair 21
dc.subject.meshCytogenetics
dc.subject.meshFemale
dc.subject.meshGene Amplification
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshPrognosis
dc.subject.meshSurvival Rate
dc.titlePrognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).en
dc.typeArticleen
dc.contributor.departmentLeukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, United Kingdom. avm@soton.ac.uken
dc.identifier.journalBlooden
html.description.abstractPatients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.


This item appears in the following Collection(s)

Show simple item record